Franklin's Experience to Bring Growth and Leadership
CARY, N.C., Oct. 29 /PRNewswire/ -- Cornerstone Therapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced that Josh Franklin has joined the company as vice president, Marketing.
Craig Collard, Cornerstone's president and chief executive officer, welcomed Franklin to the company, noting that "Josh's skills in pharmaceutical brand management and his leadership experience in a growth environment will be key as Cornerstone transitions into a publicly-held company." As announced in May Cornerstone plans to go public through a merger with Critical Therapeutics (Nasdaq: CRTX), which is scheduled to close in Q4 2008.
Before his Cornerstone appointment, Franklin was a key member of the marketing team at St. Louis, Mo.-based Ther-Rx Corporation (a subsidiary of KV Pharmaceutical) during a critical five-year growth period, serving most recently as vice president, Marketing. In previous positions, Franklin filled marketing roles with Biovail Pharmaceuticals and Ross Products Division, Abbott Labs. In these positions, he launched and managed products throughout various lifecycle phases in multiple therapeutic categories.
"I know I'm joining Cornerstone at a pivotal time," said Franklin, returning to North Carolina for the second time in his career. "And, I'm looking forward to helping lead not only the evolution of products and processes but also the company itself as our organization elevates to the next level."
A U.S. Army veteran, Mr. Franklin holds a B.S. in Business Administration from Methodist University, and M.H.A. and M.B.A. degrees from The Ohio State University.
ABOUT CORNERSTONE THERAPEUTICS, INC.
Cornerstone BioPharma Holdings, Inc., located in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. Cornerstone currently promotes four marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone's commercial strategy is to acquire non-promoted or underperforming branded pharmaceutical products and then maximize their potential value by promoting the products using its sales and marketing capabilities and applying various product life cycle management techniques. Cornerstone's product development pipeline consists of three line extensions of one of its currently marketed products and three other product candidates for the respiratory market. Cornerstone also generates revenue from the sale of six marketed product lines that include products that it does not promote.
|SOURCE Cornerstone Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved